Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences (Nasdaq: SLDB) announced on December 1, 2025 that it granted a total of 23,284 restricted stock units (RSUs) to two newly hired employees as inducement awards under the company’s 2024 Inducement Stock Incentive Plan.

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) announced on December 1, 2025 that it granted a total of 23,284 restricted stock units (RSUs) to two newly hired employees as inducement awards under the company’s 2024 Inducement Stock Incentive Plan.

The RSUs vest in four equal installments on each one-year anniversary of the grant date through the fourth anniversary, and vesting is subject to the employees' continued service. The awards were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

Argus Dec 2 session

-2.11% close to close Open Argus

Details

News Market Reaction – SLDB

On Dec 2, the first trading day after this news, SLDB closed 2.11% below the previous close.

Data tracked by StockTitan Argus for the Dec 2 session.

Key Figures

RSU grants: 23,284 RSUs Employees granted: 2 employees Vesting schedule: 4 annual installments +1 more

RSU grants

23,284 RSUs

Inducement awards to two newly hired employees

Employees granted

2 employees

Recipients of 2024 Inducement Plan RSU awards

Vesting schedule

4 annual installments

RSUs vest over four years on each grant anniversary

Inducement plan year

2024

2024 Inducement Stock Incentive Plan used for grants

Historical Context

5 past events · Latest: Dec 08

5 events

1. Dec 08

   Clinical data presentations

   24h Move

   -1.0%

   New data on AAV-SLB101 and cardiac gene therapy program at CVCT Forum.

2. Dec 01

   Equity inducement grants

   24h Move

   -2.1%

   Grant of 23,284 RSUs to two new employees under inducement plan.

3. Dec 01

   Regulatory designation

   24h Move

   -4.0%

   FDA Rare Pediatric Disease designation for SGT-212 gene therapy program.

4. Nov 17

   Licensing agreement

   24h Move

   +2.4%

   Non-exclusive global license for AAV-SLB101 with Andelyn Biosciences.

5. Nov 11

   Investor conferences

   24h Move

   +9.2%

   Participation in Jefferies and Piper Sandler healthcare investor conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4), inducement stock incentive plan

4 terms

restricted stock units financial

"announced grants of 23,284 restricted stock units (“RSUs”)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"restricted stock units (“RSUs”) to two newly hired employees"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement stock incentive plan financial

"pursuant to the Company’s 2024 Inducement Stock Incentive Plan"

An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 23,284 restricted stock units (“RSUs”) to two newly hired employees.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Solid Biosciences (SLDB) announce on December 1, 2025 about employee equity?

The company granted 23,284 RSUs to two newly hired employees as inducement awards under its 2024 Inducement Stock Incentive Plan.

How do the RSUs granted by SLDB vest and what is the timeline?

The RSUs vest in four equal annual installments, on each one-year anniversary of the grant date through year four, subject to continued service.

Under which plan and Nasdaq rule were the Solid Biosciences RSUs granted?

The grants were made under the 2024 Inducement Stock Incentive Plan as inducements consistent with Nasdaq Listing Rule 5635(c)(4).

How many employees received RSUs in the Solid Biosciences December 1, 2025 grant?

Two newly hired employees received the total award of 23,284 RSUs.

Are the RSU awards from SLDB conditional or guaranteed?

Vesting of the RSUs is conditional on each employee's continued service with the company through each vesting date.